Navigation Links
CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive

Boston, MA May 24, 2010 CardioCareLive, the world's largest live online cardiology congress presented by the Johns Hopkins University School of Medicine, today announced three new complimentary Continuing Medical Education (CME) Summits to be held over two days on Tuesday June 28th and Wednesday June 29th offering topics of interest to cardiovascular care and internal medicine and family care physicians in Atrial Fibrillation, Interventional Cardiology and Lipids. The Atrial Fibrillation Summit at CardioCareLive is supported by educational grants from Bristol-Myers Squibb and Pfizer, Inc. and Boehringer Ingelheim, the Interventional Cardiology Summit is supported by an educational grant from Daiichi/Lilly and the Lipids Summit at CardioCareLive is supported by an educational grant from Merck & Co.

The Cardiovascular Research Foundation is joining Johns Hopkins in presenting four sessions within the Interventional Cardiology Summit beginning at 2:00 PM EDT on Tuesday June 28th. The Cardiovascular Research Foundation's mission is to improve the survival and quality of life for people with cardiovascular disease through research and education.

CardioCareLive enables physicians, nurse practitioners and physician assistants and other healthcare practitioners to stay current on advances in cardiovascular care at no cost by viewing streaming video CME presentations featuring recognized cardiology experts from the convenience of any computer. A total of 12 AMA PRA Category I Credits will be available during the live programming June 28th and June 29th in addition to the 13 AMA PRA Category I Credits currently available on demand in enduring format at CardioCareLive. It is complimentary to register and attend any program at CardioCareLive.

Physicians from the nation's most respected teaching hospitals and cardiology care associations will act as activity directors for the three programs over two days at CardioCareLive. Dr. Roger Blumenthal, Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, will be the Activity Director for the Atrial Fibrillation, Interventional Cardiology and Lipids Summits. He will be joined by Dr. Gregg Stone, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation, as activity director for the Interventional Cardiology summit. Dr. Chris Cannon, Associate Professor of Medicine at Harvard Medical School and Associate Physician, Cardiovascular Division at Brigham and Women's Hospital, will join Dr. Roger Blumenthal as Activity Director for the Atrial Fibrillation and Lipids summits.

Live programming begins on Tuesday June 28th at 9:00 AM EDT and again on Wednesday June 29th at 11:00 AM EDT, with individual presentations beginning on the hour. Practitioners who attend live may take advantage of interactive capabilities by texting in questions to be addressed live -online by presenting faculty. Each session will be available in on demand (enduring) format as soon as the session concludes. The agenda features the following topics:

Are We Getting Better at Identifying AF Patients at High Risk of Stroke?
Stroke Prevention in AF: Putting the Current Guidelines Into Clinical Practice
New Frontiers in Stroke Prevention in the AF Setting: A Focus on Unmet Patients' Needs
Optimizing Therapy Choices to Prevent Stroke in Patients With AF

In partnership with the Cardiovascular Research Foundation
Clinical Perspectives in Stent Thrombosis: A Focus on Prevention and Management
Optimizing Performance Measures to Improve STEMI Outcomes Syndromes
Who Is at Risk of Antiplatelet Resistance: From Genetics to Clinical Relevance
Stents in Patients With Stable Angina: Overused or Misunderstood?

Optimizing Current Strategies with Statins: A Focus on New Evidence
Moving Beyond Statin Treatment in Dyslipidemias
Emerging Therapies and Their Role in Comprehensive Lipid Management
Management of Residual Cardiovascular Risk


Contact: Judy Romero
Cardiovascular Research Foundation

Related medicine news :

1. Women More Likely to Fail Treatment for Atrial Fibrillation
2. In Tests, Implanted Monitor Detects Atrial Fibrillation
3. Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation
4. People with diabetes are at higher risk of atrial fibrillation
5. BioSTARTM device achieves 90 percent closure rate for atrial septal defect in children
6. Having Relative With Atrial Fibrillation Raises Own Risk
7. New trial studies link between stroke and atrial fibrillation
8. Heavy Drinking May Boost Risk for Atrial Fibrillation
9. Blood Pressure Drug Does Not Help Those With Atrial Fibrillation
10. Data evaluates rehospitalization and cost burden of AFib/atrial flutter
11. Cryoablation used to successfully treat atrial fibrillation at the Montreal Heart Institute
Post Your Comments:
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary ... Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 as ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology: